WuXi Biologics (Cayman) Inc. delivered solid FY2025 results, with revenue of HK$21.79B and net income of HK$4.91B. The company continues to demonstrate resilience across its core business segments, supported by Biotechnology demand tailwinds and disciplined cost management. Free cash flow generation
Access the complete analysis, financial model, price target breakdown, and risk factors.
Read Full Report →2 free reads per day · No credit card required